China Inactivated HAV Vaccine For Pediatric And Adult Immunization Manufacturer, Supplier, Factory

AIM Honesty Biopharmaceutical Co., Ltd. is a China manufacturer specializing in Inactivated HAV Vaccine For Pediatric And Adult Immunization. Developed with human diploid cell technology, this vaccine uses the HAV Lv-8 strain cultured in KMB17 human diploid cells and is manufactured through virus purification and inactivation procedures. With product approval information such as NMPA Approval Number S20153002, it is designed to support hepatitis A prevention programs requiring clear dosage options for both children and adults.

When healthcare organizations select hepatitis A vaccines, the key consideration is not only the product name but also whether the vaccine technology, age application, dosage information, and supply capability match actual immunization requirements. AIM Action Biopharmaceutical Co., Ltd. develops its hepatitis A vaccine based on human diploid cell culture technology, providing a product option for vaccination programs covering different age groups.

Product Understanding

Inactivated HAV Vaccine For Pediatric And Adult Immunization is a preventive biological product designed to stimulate immunity against hepatitis A virus (HAV). Unlike vaccines containing live viruses, inactivated vaccines use processed viral antigens to activate the immune response while removing the ability of the virus to replicate.

The hepatitis A virus belongs to the Picornaviridae family. Its genome is a single-stranded positive-sense RNA with approximately 7500 nucleotides. HAV infection mainly affects the liver, making prevention through vaccination an important part of public health management.

For procurement teams, understanding the relationship between vaccine technology and target population helps avoid unsuitable product selection. Pediatric and adult vaccination programs often require different antigen content and dosage specifications, which should be clearly considered before purchasing.

Production Technology

The manufacturing process of AIM Action's hepatitis A vaccine is based on the human diploid cell line KMB17. The HAV Lv-8 strain is cultured in this cell substrate, and the harvested virus suspension undergoes purification, concentration, and chromatography procedures before formaldehyde solution is added for virus inactivation.

This production route focuses on maintaining antigen characteristics while preparing a vaccine suitable for immunization use. For vaccine distributors and healthcare institutions, a clear understanding of production technology helps evaluate product consistency and manufacturing background.

Key production characteristics include:

1. Human diploid cell substrate: KMB17 is a human diploid cell line independently established by the Kunming Institute in 1974. The cell line has been used as a controlled culture substrate for vaccine production.

2. Lv-8 hepatitis A virus strain: The Lv-8 strain was isolated and screened by the Kunming Institute during the 1988 Shanghai hepatitis A outbreak from a typical hepatitis A patient in Lüsi Town, Jiangsu Province. According to the provided product information, this strain features stable characteristics, high virus yield, short replication cycle, and good immunogenicity.

3. Inactivation preparation: After virus cultivation and purification, formaldehyde solution is used for inactivation to prepare the final vaccine ingredient.

Children And Adults

A common challenge in hepatitis A vaccination management is selecting the correct dosage for different age groups. Pediatric and adult populations have different vaccination requirements, so accurate product matching is important for hospitals, clinics, and immunization organizations.

Choosing the correct specification reduces confusion during vaccination planning. For example, organizations managing childhood immunization programs need pediatric doses, while adult health programs require formulations with higher antigen content according to product specifications.

Why Inactivated Design Matters

For many vaccination programs, safety characteristics and predictable administration procedures are important purchasing factors. Inactivated vaccine technology is widely used because the virus is processed to remove replication capability while retaining antigen properties needed to stimulate immunity.

Compared with products that require different handling considerations, inactivated hepatitis A vaccines provide healthcare providers with a clear production principle and standardized dosage management approach.

The main considerations for purchasers include:

1. Clear safety mechanism: The virus is inactivated during manufacturing, making the product suitable for preventive immunization applications.

2. Defined dosage system: Separate pediatric and adult specifications make it easier for healthcare providers to organize vaccination schedules.

3. Manufacturing transparency: Information about cell substrate, virus strain, and preparation process supports professional supplier evaluation.

Specification Details

For vaccine procurement, product specifications directly affect storage planning, vaccination arrangements, and population coverage. Clear dosage information allows distributors and healthcare institutions to select suitable products according to different immunization requirements.

Before administration, the vaccine should be shaken well. Following correct storage and handling procedures helps maintain product quality throughout distribution and use.

Immune Performance

When selecting vaccines for immunization programs, purchasers usually focus on whether the product can generate an effective immune response and whether the available data supports its application. According to the product information provided by AIM Action, the hepatitis A inactivated vaccine has shown good immune effects in both adults and children.

The antibody conversion rate is similar to that of imported hepatitis A inactivated vaccines, while the geometric mean titer (GMT, mIU/mL) of antibodies is better than imported hepatitis A inactivated vaccines according to the provided product information.

This information can help healthcare organizations evaluate product performance when comparing available hepatitis A vaccine options for different vaccination programs.

Distribution Support

Vaccine supply management requires attention not only to product performance but also to transportation conditions, inventory planning, and application requirements. For distributors and healthcare organizations, selecting a supplier with established vaccine manufacturing experience can simplify procurement decisions.

AIM Action's vaccine production system focuses on standardized manufacturing procedures and pharmaceutical quality management. The company provides vaccine products based on its research and manufacturing capabilities, supporting organizations that require hepatitis A prevention products.

During procurement evaluation, buyers usually consider:

1. Product documentation: Complete product information helps distributors and medical organizations understand dosage, storage, and usage requirements.

2. Supply consistency: Stable production management is important for vaccination programs requiring continuous product availability.

3. Technical background: Manufacturing experience, research capability, and production technology are important factors when choosing a vaccine partner.

Application Considerations

An effective vaccination program requires matching the Inactivated HAV Vaccine For Pediatric And Adult Immunization specification with the actual population being served. Pediatric and adult immunization projects may involve different scheduling, storage planning, and management procedures.

Common application considerations include:

1. Population planning: Confirm the target age group before selecting the corresponding dosage specification.

2. Vaccination scheduling: According to the provided product information, a primary immunization dose is followed by a booster dose after 6 months.

3. Professional administration: Vaccination should be performed according to professional medical guidance and product instructions.

FAQ

Q: What is the purpose of an inactivated hepatitis A vaccine?

A: An inactivated hepatitis A vaccine is used to stimulate the immune system to recognize hepatitis A virus and develop immunity for preventive healthcare purposes. The virus is processed through an inactivation procedure during manufacturing.

Q: What age groups can use this hepatitis A vaccine?

A: According to the provided product information, different dosage specifications are available for children aged 1-15 years old and adults over 15 years old. Healthcare providers should select the appropriate specification based on age requirements.

Q: What is the difference between the children's and adult formulations?

A: The children's formulation contains 320 EU of hepatitis A virus antigen in a 0.5ml dose, while the adult formulation contains 640 EU of hepatitis A virus antigen in a 1.0ml dose.

Q: Why does the production process use KMB17 human diploid cells?

A: KMB17 is a human diploid cell line independently established by the Kunming Institute in 1974. It is used as the cell substrate for cultivating the hepatitis A virus strain during vaccine production.

Q: How should the product be stored during transportation?

A: According to the provided product information, the vaccine should be stored and transported at 2-8℃ and protected from light to maintain product quality.

Q: What information should buyers confirm before placing an order?

A: Buyers should confirm product specifications, dosage requirements, storage conditions, documentation, and application needs to ensure the selected vaccine matches their immunization program requirements.

Final Overview

Selecting a hepatitis A vaccine requires balancing technology, dosage requirements, application scenarios, and supply considerations. AIM Action's vaccine is developed using human diploid cell technology with the Lv-8 hepatitis A virus strain and provides pediatric and adult dosage options for different immunization needs.

With clear specifications, established production procedures, and product information covering different age groups, this vaccine supports healthcare organizations and distributors seeking a practical option for hepatitis A prevention programs.